Investors

DermaLumics‘ success has only been possible due the credibility and the sustainability that was given to his project by their investors

logo-ysios-capital

 

Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. They target the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices.

Founded in 2008, Ysios Capital has € 118 million in assets under management distributed over two funds. The second fund has a target size of € 100 million and will remain open to new investors until September 2015.

Their team includes experienced professionals with extensive complementary expertise in investing and building healthcare and biotechnology companies. Ysios Capital has access to a broad global network within academia, finance and industry. They take an active role in the development of their portfolio companies as a lead investor or as an active syndicate partner.

Ysios Capital is registered at the Spanish Securities and Exchange Commission (CNMV). Its main office is in Barcelona.

The current portfolio de Ysios Capital is:

  • AM-Pharma (Netherlands);
  • CVRx (USA);
  • Inbiomotion (Spain);
  • Kala Pharmaceuticals (USA);
  • MedLumics (Spain);
  • STAT-Diagnostica (Spain);
  • TiGenix (Belgium).

ENLIGHTENING SKINCARE